Ultra high affinity neutralizing antibodies

US6656467B2 · kind B2 · utility

Assignees

• MedImmune Limited · US
• Applied Molecular Evolution, Inc. · US

Inventors

• James F. Young · Potomac, US
• Leslie S. Johnson · Germantown, US
• William D. Huse · Del Mar, US
• Herren Wu · Boyds, US
• Jeffry D. Watkins · Encinitas, US

Key dates

• Filing date: Jan 26, 2001
• Grant date: Dec 2, 2003
• Expiry date: Jan 26, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.